<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147691</url>
  </required_header>
  <id_info>
    <org_study_id>FIN1302</org_study_id>
    <nct_id>NCT02147691</nct_id>
  </id_info>
  <brief_title>Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study</brief_title>
  <official_title>Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pilot study will investigate whether combination treatment of Finacea 15% Gel and
      Brimonidine 0.33% Gel could be more effective than Brimonidine 0.33% Gel monotherapy in
      treating both the papules/pustules and erythema associated with rosacea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acne rosacea is a chronic inflammatory disease with different components including
      inflammatory lesions (papules/pustules), erythema and telangiectasia. Brimonidine 0.33% Gel
      primarily affects the erythematous components of rosacea. As such, combination treatment with
      a standard rosacea treatment, such as Finacea 15% Gel, may provide additional relief for the
      inflammatory component of rosacea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment (IGA) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGA</measure>
    <time_frame>Week 4</time_frame>
    <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGA</measure>
    <time_frame>Week 8</time_frame>
    <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGA</measure>
    <time_frame>Week 12</time_frame>
    <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion Counts</measure>
    <time_frame>Baseline</time_frame>
    <description>The number of inflammatory lesions (papules/pustules) will be counted using the whole face from the hairline edge to the mandibular line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician's Erythema Assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>Erythema will be graded on a scale of 0-4., 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 very severe. If erythema is much worse on one or several parts of the face, the grade for the worst area will be captured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema Visual Analog Scale (VAS) Assessment (Subject)</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjects will self assess the level of erythema over the previous 24 period using a scale of None (0) through 10 (Unbearable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline</time_frame>
    <description>The DLQI is a self-administered questionnaire consisting of 10 questions that measure how much the individual's skin problem has affected their life in the past week. Score ranges 0 through 30, 0 being none and 30 worst possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Count</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Counts</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Counts</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>Week 4</time_frame>
    <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>Week 8</time_frame>
    <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>Week 12</time_frame>
    <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>Week 4</time_frame>
    <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS</measure>
    <time_frame>Week 8</time_frame>
    <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS</measure>
    <time_frame>Week 12</time_frame>
    <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 4</time_frame>
    <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI</measure>
    <time_frame>Week 8</time_frame>
    <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI</measure>
    <time_frame>Week 12</time_frame>
    <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Acne Rosacea</condition>
  <arm_group>
    <arm_group_label>Azelaic acid 15%, Brimonidine 0.33 % Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%
Azelaic acid 15% to the face each PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine 0.33% Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine 0.33% Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid 15%</intervention_name>
    <description>Applied to the face each AM and PM</description>
    <arm_group_label>Azelaic acid 15%, Brimonidine 0.33 % Gel</arm_group_label>
    <other_name>Finacea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine 0.33%</intervention_name>
    <description>Applied to the face each AM 30 minutes after the application of Azelaic acid 15%</description>
    <arm_group_label>Azelaic acid 15%, Brimonidine 0.33 % Gel</arm_group_label>
    <arm_group_label>Brimonidine 0.33% Gel</arm_group_label>
    <other_name>Miravaso</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female

          -  18 years of age and older

          -  Female subjects of childbearing potential must have a negative urine pregnancy test at
             Baseline

          -  Female subjects of childbearing potential must practice a reliable method of
             contraception throughout the study

          -  Moderate or severe rosacea with an Investigator Global Assessment (IGA) score of 3 or
             4

          -  Able to understand and comply with the requirements of the study and sign Informed
             Consent/Health Insurance Portability and Accountability Authorization forms

        Exclusion Criteria:

          -  Female subjects who are pregnant, breast feeding or who are of childbearing potential
             and not practicing a reliable method of birthcontrol

          -  History of hypersensitivity or idiosyncratic reaction to any component of the test
             medications

          -  Subjects who have not completed the proper wash-out periods for prohibited medications
             and/or procedures

          -  Medical condition that contraindicates the subject's participation in the study

          -  Alcohol or drug abuse is evident within the past 5 years

          -  History of poor cooperation, non-compliance with medical treatment, unreliability

          -  Participation in an investigational drug study within 30 days of the Baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon H. Kircik, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch, PLLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <results_first_submitted>May 7, 2015</results_first_submitted>
  <results_first_submitted_qc>August 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2015</results_first_posted>
  <last_update_submitted>August 28, 2015</last_update_submitted>
  <last_update_submitted_qc>August 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Derm Research, PLLC</investigator_affiliation>
    <investigator_full_name>Leon Kircik, M.D.</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Single site recruitment, private medical clinic.. Subjects 18 to 85 years of age with moderate to severe rosacea.Recruitment began May 2014 and ended November 2014.</recruitment_details>
      <pre_assignment_details>Subjects could be excluded if less than 18 years of age, who does not have moderate to severe rosacea as determined by the Investigator Global Assessment (IGA), who has not completed the specified washout for medications as outlined in the protocol or who has been in another investigational study within 30 days of the Baseline visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 0.33 % Gel</title>
          <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
        </group>
        <group group_id="P2">
          <title>Brimonidine 0.33% Gel</title>
          <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidine 0.33%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>subjects between 18 years and 85 years of age with moderate to severe rosacea</population>
      <group_list>
        <group group_id="B1">
          <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
          <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
        </group>
        <group group_id="B2">
          <title>Brimonidine 0.33% Gel</title>
          <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidine 0.33%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator Global Assessment (IGA) at Baseline</title>
        <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
        <time_frame>Baseline</time_frame>
        <population>Only participants who were not lost to follow up or did not withdraw consent were included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment (IGA) at Baseline</title>
          <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
          <population>Only participants who were not lost to follow up or did not withdraw consent were included in the final analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0"/>
                    <measurement group_id="O2" value="3.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Counts</title>
        <description>The number of inflammatory lesions (papules/pustules) will be counted using the whole face from the hairline edge to the mandibular line</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Counts</title>
          <description>The number of inflammatory lesions (papules/pustules) will be counted using the whole face from the hairline edge to the mandibular line</description>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.6"/>
                    <measurement group_id="O2" value="4.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician's Erythema Assessment</title>
        <description>Erythema will be graded on a scale of 0-4., 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 very severe. If erythema is much worse on one or several parts of the face, the grade for the worst area will be captured.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician's Erythema Assessment</title>
          <description>Erythema will be graded on a scale of 0-4., 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 very severe. If erythema is much worse on one or several parts of the face, the grade for the worst area will be captured.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.5"/>
                    <measurement group_id="O2" value="2.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema Visual Analog Scale (VAS) Assessment (Subject)</title>
        <description>Subjects will self assess the level of erythema over the previous 24 period using a scale of None (0) through 10 (Unbearable)</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Visual Analog Scale (VAS) Assessment (Subject)</title>
          <description>Subjects will self assess the level of erythema over the previous 24 period using a scale of None (0) through 10 (Unbearable)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.5"/>
                    <measurement group_id="O2" value="5.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI)</title>
        <description>The DLQI is a self-administered questionnaire consisting of 10 questions that measure how much the individual's skin problem has affected their life in the past week. Score ranges 0 through 30, 0 being none and 30 worst possible.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI)</title>
          <description>The DLQI is a self-administered questionnaire consisting of 10 questions that measure how much the individual's skin problem has affected their life in the past week. Score ranges 0 through 30, 0 being none and 30 worst possible.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.7"/>
                    <measurement group_id="O2" value="2.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IGA</title>
        <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>IGA</title>
          <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.9"/>
                    <measurement group_id="O2" value="1.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IGA</title>
        <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>IGA</title>
          <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.2"/>
                    <measurement group_id="O2" value="1.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IGA</title>
        <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>IGA</title>
          <description>Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.1"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Count</title>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Count</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.2"/>
                    <measurement group_id="O2" value="2.1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Counts</title>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Counts</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.4"/>
                    <measurement group_id="O2" value="1.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Counts</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Counts</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.3"/>
                    <measurement group_id="O2" value="1.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema</title>
        <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema</title>
          <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema</title>
        <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema</title>
          <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.8"/>
                    <measurement group_id="O2" value="1.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema</title>
        <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema</title>
          <description>Erythema as measured by the clinician on a scale of 0-4, 0 = no erythema, 1 = slight pinkness, 2 = moderate, definite redness, easily recognized, 3 = severe, marked erythema and 4 = very severe, fiery red</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.7"/>
                    <measurement group_id="O2" value="1.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS)</title>
        <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS)</title>
          <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="2.4"/>
                    <measurement group_id="O2" value="5.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS</title>
        <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>VAS</title>
          <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="3.0"/>
                    <measurement group_id="O2" value="4.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS</title>
        <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>VAS</title>
          <description>participant measures erythema on a scale of 0 mm to 10 mm with 0 = to none and 10 = unbearable</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.3"/>
                    <measurement group_id="O2" value="4.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI)</title>
        <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI)</title>
          <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.5"/>
                    <measurement group_id="O2" value="2.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DLQI</title>
        <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>DLQI</title>
          <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.2"/>
                    <measurement group_id="O2" value="2.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DLQI</title>
        <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
            <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine 0.33% Gel</title>
            <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
          </group>
        </group_list>
        <measure>
          <title>DLQI</title>
          <description>Total scores range from 0 ( no impact on life over the last week) to 30 (maximum impact on life over the last week)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.2"/>
                    <measurement group_id="O2" value="2.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Finacea 15% Gel (Azelaic Acid 15%), Brimonidine 15 % Gel</title>
          <description>Finacea 15% Gel (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face
Finacea 15 % Gel (azelaic acid 15%) each evening to the face
Azelaic acid 15%
Brimonidine 0.33%</description>
        </group>
        <group group_id="E2">
          <title>Brimonidine 0.33% Gel</title>
          <description>Brimonidine 0.33% Gel applied to the face each morning
Brimonidone 0.33%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pulled muscle</sub_title>
                <description>right hip</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Broken toe</sub_title>
                <description>Left fourth toe</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>common cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>worsening erythema on face</sub_title>
                <description>treatment area</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>worsening facial lesions</sub_title>
                <description>treatment area</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>herpes simplex</sub_title>
                <description>Adjacent to treatment area</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>burning at application site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot study. Small number of participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Leon H. Kircik, M.D.</name_or_title>
      <organization>DermResearch, PLLC</organization>
      <phone>502-451-9000</phone>
      <email>wedoderm@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

